Current concepts of anticoagulant therapy in pregnancy.
The optimal use of anticoagulants during pregnancy will continue to be controversial until appropriate randomized controlled and prospective trials with adequate sample sizes are completed. The relative low frequency of thromboembolic events, the concerns about maternal and fetal safety of both treatment and withholding treatment, and the reservations about prospectively enrolling pregnant women in treatment trials has sadly dissuaded the appropriate study of this life-threatening condition. North American trials that enroll pregnant women to evaluate the efficacy of LMWH are of preeminent importance owing to their superior bioavailability, ease in dosing, longer half-life, and side effect profile. Similarly, trials evaluating the optimal management of women of childbearing age with valvular disease are critical to reduce the considerable maternal and fetal morbidity and mortality associated with these pregnancies. Such definitive studies will need to be multicenter in design and it is hoped that the National Institutes of Health initiative to enroll pregnant women in clinical trials will at last be realized in the near future.
Barbour
L A
LA
Department of Medicine, University of Colorado Health Sciences Center, Denver, USA.
D000925:Anticoagulants / Q000627:therapeutic use*; D004739:England; D005260:Female; D006349:Heart Valve Diseases / Q000188:drug therapy* / Q000517:prevention & control; D006493:Heparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy* / Q000453:epidemiology; D013548:Sweden; D013923:Thromboembolism / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D015912:Thrombolytic Therapy; D014481:United States; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D014859:Warfarin; D006493:Heparin